BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 26968247)

  • 1. Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells.
    Göbel A; Thiele S; Browne AJ; Rauner M; Zinna VM; Hofbauer LC; Rachner TD
    Cancer Lett; 2016 May; 375(1):162-171. PubMed ID: 26968247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins.
    Göbel A; Browne AJ; Thiele S; Rauner M; Hofbauer LC; Rachner TD
    Breast Cancer Res Treat; 2015 Dec; 154(3):623-31. PubMed ID: 26515701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells.
    Ebert R; Meissner-Weigl J; Zeck S; Määttä J; Auriola S; Coimbra de Sousa S; Mentrup B; Graser S; Rachner TD; Hofbauer LC; Jakob F
    Mol Cancer; 2014 Dec; 13():265. PubMed ID: 25496233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
    Jagdev SP; Coleman RE; Shipman CM; Rostami-H A; Croucher PI
    Br J Cancer; 2001 Apr; 84(8):1126-34. PubMed ID: 11308265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer.
    Göbel A; Zinna VM; Dell'Endice S; Jaschke N; Kuhlmann JD; Wimberger P; Rachner TD
    BMC Cancer; 2020 Jul; 20(1):703. PubMed ID: 32727400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dickkopf-1 is regulated by the mevalonate pathway in breast cancer.
    Rachner TD; Göbel A; Thiele S; Rauner M; Benad-Mehner P; Hadji P; Bauer T; Muders MH; Baretton GB; Jakob F; Ebert R; Bornhäuser M; Schem C; Hofbauer LC
    Breast Cancer Res; 2014 Feb; 16(1):R20. PubMed ID: 24528599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
    Oades GM; Senaratne SG; Clarke IA; Kirby RS; Colston KW
    J Urol; 2003 Jul; 170(1):246-52. PubMed ID: 12796698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
    Morgan C; Lewis PD; Jones RM; Bertelli G; Thomas GA; Leonard RC
    Acta Oncol; 2007; 46(5):669-77. PubMed ID: 17562444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells.
    Merrell MA; Wakchoure S; Lehenkari PP; Harris KW; Selander KS
    Eur J Pharmacol; 2007 Sep; 570(1-3):27-37. PubMed ID: 17640631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay.
    Knight LA; Kurbacher CM; Glaysher S; Fernando A; Reichelt R; Dexel S; Reinhold U; Cree IA
    BMC Cancer; 2009 Jan; 9():38. PubMed ID: 19175937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic Antiproliferative Effects of Zoledronic Acid and Fluvastatin on Human Pancreatic Cancer Cell Lines: An in Vitro Study.
    Elsayed M; Kobayashi D; Kubota T; Matsunaga N; Murata R; Yoshizawa Y; Watanabe N; Matsuura T; Tsurudome Y; Ogino T; Ohdo S; Shimazoe T
    Biol Pharm Bull; 2016 Aug; 39(8):1238-46. PubMed ID: 27181081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Krüppel-like factors KLF2 and 6 and Ki-67 are direct targets of zoledronic acid in MCF-7 cells.
    Ebert R; Zeck S; Meissner-Weigl J; Klotz B; Rachner TD; Benad P; Klein-Hitpass L; Rudert M; Hofbauer LC; Jakob F
    Bone; 2012 Mar; 50(3):723-32. PubMed ID: 22166808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The balance between induction and inhibition of mevalonate pathway regulates cancer suppression by statins: A review of molecular mechanisms.
    Ahmadi Y; Ghorbanihaghjo A; Argani H
    Chem Biol Interact; 2017 Aug; 273():273-285. PubMed ID: 28668359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gamma-tocotrienol reverses multidrug resistance of breast cancer cells with a mechanism distinct from that of atorvastatin.
    Ding Y; Peng Y; Deng L; Fan J; Huang B
    J Steroid Biochem Mol Biol; 2017 Mar; 167():67-77. PubMed ID: 27864002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue.
    Reinholz GG; Getz B; Sanders ES; Karpeisky MY; Padyukova NSh; Mikhailov SN; Ingle JN; Spelsberg TC
    Breast Cancer Res Treat; 2002 Feb; 71(3):257-68. PubMed ID: 12002344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines.
    Ibrahim T; Liverani C; Mercatali L; Sacanna E; Zanoni M; Fabbri F; Zoli W; Amadori D
    Int J Oncol; 2013 Apr; 42(4):1263-70. PubMed ID: 23403907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mevalonate Cascade Inhibition by Simvastatin Induces the Intrinsic Apoptosis Pathway via Depletion of Isoprenoids in Tumor Cells.
    Alizadeh J; Zeki AA; Mirzaei N; Tewary S; Rezaei Moghadam A; Glogowska A; Nagakannan P; Eftekharpour E; Wiechec E; Gordon JW; Xu FY; Field JT; Yoneda KY; Kenyon NJ; Hashemi M; Hatch GM; Hombach-Klonisch S; Klonisch T; Ghavami S
    Sci Rep; 2017 Mar; 7():44841. PubMed ID: 28344327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells.
    Journé F; Kheddoumi N; Chaboteaux C; Duvillier H; Laurent G; Body JJ
    Breast Cancer Res; 2008; 10(1):R4. PubMed ID: 18190680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells.
    Göbel A; Breining D; Rauner M; Hofbauer LC; Rachner TD
    Cell Death Dis; 2019 Jan; 10(2):91. PubMed ID: 30692522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel aspects of mevalonate pathway inhibitors as antitumor agents.
    Thurnher M; Nussbaumer O; Gruenbacher G
    Clin Cancer Res; 2012 Jul; 18(13):3524-31. PubMed ID: 22529099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.